Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Tirofiban can be used to treat STEMI, study shows

  • Comment
High doses of the drug tirofiban is as effective as abciximab in reducing ST-segment elevation in patients with ST-elevation myocardial infarction (STEMI), a study has shown.

Tirofiban, manufactured under the trade name Aggrastat by MSD, is only currently licensed in the UK for use in treatment of non-STEMI patients.

Findings from the three-year open-label trial of 745 patients with STEMI in Italy, Spain and Argentina showed at least 50% recovery from ST-elevation in 85.3% and 83.6% of patients in tirofiban and abciximab groups respectively.

Tirofiban was administered at first medical contact before arterial or sheath insertion, as a bolus of 25 ug/kg followed by an 18-24 hour infusion at 0.15 ug/kg/min.

After a follow-up period of eight months, the incidence of major adverse cardiac events was approximately 20% lower in patients treated with tirofiban compared with abciximab (9.8% compared with 12.4%).

Findings were presented at the 57th Annual Scientific Session of the American College of Cardiology and were published online by the Journal of the American Medical Association (JAMA).

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs